Tautomeric and non-tautomeric N-substituted 2-iminobenzimidazolines as new lead compounds for the design of anti-influenza drugs: An in vitro study

Add time:08/11/2019    Source:sciencedirect.com

A series of 1,3-disubstituted 2-iminobenzimidazolines as well as a number of their tautomeric analogs were synthesized. The synthesized compounds were tested for their cytotoxicity against MDCK cells and for inhibiting activity against influenza virus A/California/07/09 (H1N1)pdm09. Based on the results obtained, 50% cytotoxic concentration (CC50), 50% inhibiting concentration (IC50) and selectivity index (SI) were calculated for each compound. It was found that some of synthesized benzimidazole derivatives (7 of 22, 32%) possess strong virus-inhibiting activity against pandemic influenza virus (IC50’s in low micromolar range) with quite moderate cytotoxicity (CC50 in the range of thousands micromoles). Due to their high selectivity (highest SI’s = 50–83) these compounds are of significant interest for further in vivo experiments as well as for further structural optimization and drug development.

We also recommend Trading Suppliers and Manufacturers of 2-[(1-methyl-2-phenoxyethyl)amino]ethanol (cas 103-39-9). Pls Click Website Link as below: cas 103-39-9 suppliers

Prev:Chitosan as biosupport for the MW-assisted synthesis of palladium catalysts and their use in the hydrogenation of Ethyl cinnamate (cas 103-36-6)
Next:Regular ArticleINSULINOTROPIC ACTION OF NOVEL SUCCINIC ACID ESTERS)